Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

Biochemical Journal

Volumn 409, Issue 2, 2008, Pages 581-589

  Khan, Nagma ^a   Jeffers, Michael ^b   Kumar, Sampath ^b   Hackett, Craig ^b   Boldog, Ferenc ^b   Khramtsov, Nicholai ^b   Qian, Xiaozhong ^b   Mills, Evan ^b   Berghs, Stanny C ^b   Carey, Nessa ^a   Finn, Paul W ^a   Collins, Laura S ^a   Tumber, Anthony ^a   Ritchie, James W ^a   Jensen, Peter Buhl ^a   Lichenstein, Henri S ^b   Sehested, Maxwell ^a  

^a BioAlliance Pharma   (France)

^b CURAGEN CORPORATION   (United States)

Author keywords

Deacetylation; Histone deacetylase (HDAC); Histone deacetylase isoforms (HDAC isoforms); Small molecule inhibitors; Tubulin

Indexed keywords

DEACETYLATION; HISTONE DEACETYLASE (HDAC); HISTONE DEACETYLASE ISOFORMS (HDAC ISOFORMS); SMALL-MOLECULE INHIBITORS; TUBULIN;

ACETYLATION; BIOASSAY; CELL GROWTH; ENZYME INHIBITION; GENE EXPRESSION; ONCOLOGY;

PROTEINS;

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ANTINEOPLASTIC AGENT; APICIDIN; BELINOSTAT; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; ISOENZYME; ITF 2357; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PANOBINOSTAT; RECOMBINANT ENZYME; TRICHOSTATIN A; TUBULIN; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CELL GROWTH; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ASSAY; HELA CELL; HUMAN; HUMAN CELL; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACETYLATION; CELL PROLIFERATION; CLONING, MOLECULAR; ENZYME INHIBITORS; HELA CELLS; HISTONE DEACETYLASES; HUMANS; PROTEIN ISOFORMS; RECOMBINANT PROTEINS;

EID: 37849019672     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20070779     Document Type: Article

References (50)

1. de Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S. and van Kuilenburg, A. B. (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 370, 737-749
2. Cheung, W. L., Briggs, S. D. and Allis, C. D. (2000) Acetylation and chromosomal functions. Curr. Opin. Cell Biol. 12, 326-333
3. Cress, W. D. and Seto, E. (2000) Histone deacetylases, transcriptional control, and cancer. J. Cell Physiol. 184, 1-16
4. Strahl, B. D. and Allis, C. D. (2000) The language of covalent histone modifications. Nature 403, 41-45
5. Wade, P. A. (2001) Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum. Mol. Genet. 10, 693-698
6. Thiel, G., Lietz, M. and Hohl, M. (2004) How mammalian transcriptional repressors work. Eur. J. Biochem. 271, 2855-2862
7. Matsuyama, A., Shimazu, T., Sumida, Y., Saito, A., Yoshimatsu, Y., Seigneurin-Berny, D., Osada, H., Komatsu, Y., Nishino, N., Khochbin, S. et al. (2002) In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. 21, 6820-6831
8. Glaser, K. B., Li, J., Pease, L. J., Staver, M. J., Marcotte, P. A., Guo, J., Frey, R. R., Garland, R. B., Heyman, H. R., Wada, C. K. et al. (2004) Differential protein acetylation induced by novel histone deacetylase inhibitors. Biochem. Biophys. Res. Commun. 325, 683-690
9. Marks, P., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T. and Kelly, W. K. (2001) Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer. 1, 194-202
10. Glozak, M. A., Sengupta, N., Zhang, X. and Seto, E. (2005) Acetylation and deacetylation of non-histone proteins. Gene 363, 15-23
11. Johnstone, R. W. (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1, 287-299
12. Yoshida, M., Furumai, R., Nishiyama, M., Komatsu, Y., Nishino, N. and Horinouchi, S. (2001) Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. 48, Suppl. 1, S20-S26
13. Yoshida, M., Shimazu, T. and Matsuyama, A. (2003) Protein deacetylases: enzymes with functional diversity as novel therapeutic targets. Prog. Cell Cycle Res. 5, 269-278
14. Bertos, N. R., Wang, A. H. and Yang, X. J. (2001) Class II histone deacetylases: structure, function, and regulation. Biochem. Cell Biol. 79, 243-252
15. Gregoretti, I. V., Lee, Y. M. and Goodson, H. V. (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338, 17-31
16. Guenther, M. G., Barak, O. and Lazar, M. A. (2001) The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol. Cell Biol. 21, 6091-6101
17. Codina, A., Love, J. D., Li, Y., Lazar, M. A., Neuhaus, D. and Schwabe, J. W. (2005) Structural insights into the interaction and activation of histone deacetylase3 by nuclear receptor corepressors. Proc. Natl. Acad. Sci. U.S.A. 102, 6009-6014
18. Fischle, W., Deguiedt, F., Hendzel, M. J., Guenther, M. G., Lazar, M. A., Voelter, W. and Verdin, E. (2002) Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell. 9, 45-57
19. Zhang, Y., Gilquin, B., Khochbin, S. and Matthias, P. (2006) Two catalytic domains are required for protein deacetylation, J. Biol. Chem. 281, 2401-2404
20. Minucci, S. and Pelicci, P. G. (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6, 38-51
21. Yoo, C. B. and Jones, P. A. (2006) Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 5, 37-50
22. McLaughlin, F. and La Thangue, N. B. (2004) Histone deacetylase inhibitors open new doors in cancer therapy, Biochem. Pharmacol. 68, 1139-1144
23. Finn, P. W., Bandara, M., Butcher, C., Finn, A., Hollinshead, R., Khan, N., Law, N., Murthy, S., Romero, R., Watkins, C. et al. (2005) Novel sulfonamide derivatives as inhibitors of histone deacetylase. Helv. Chim. Acta 88, 1630-1643
24. Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E. and Robson, C. N. (2004) Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59, 177-189
25. Choi, J. H., Kwon, H. J., Yoon, B. I., Kim, J. H., Han, S. U., Joo, H. J. and Kim, D. Y. (2001) Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn. J. Cancer Res. 92, 1300-1304
26. Song, J., Noh, J. H., Lee, J. H., Eun, J. W., Ahn, Y. M., Kim, S. Y., Lee, S. H., Park, W. S., Yoo, N. J. et al. (2005) Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 113, 264-268
27. Bartling, B., Hofmann, H. S., Boettger, T., Hansen, G., Burdach, S., Silber, R. E. and Simm, A. (2005) Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma. Lung Cancer 49, 145-154
28. Sakuma, T., Uzawa, K., Onda, T., Shiiba, M., Yokoe, H., Shibahara, T. and Tanzawa, H. (2006) Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int. J. Oncol. 29, 117-124
29. Lee, H., Sengupta, N., Villagra, A., Rezai-Zadeh, N. and Seto, E. (2006) Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hEST1B) protein from ubiquitin-mediated degradation. Mol. Cell Biol. 26, 5259-5269
30. Hu, E., Dul, E., Sung, C. M., Chen, Z., Kirkpatrick, R., Zhang, G. F., Johanson, K., Liu, R., Lago, A., Hofmann, G., Macarron, R. et al. (2003) Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 307, 720-728
31. Eyupoglu, I. Y., Hahnen, E., Trankle, C., Savaskan, N. E., Siebzehnrubl, F. A., Buslei, R., Lemke, D., Wick, W., Fahlbusch, R. and Blumcke, I. (2006) Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. Mol. Cancer Ther. 5, 1248-1255
32. Kalita, A., Maroun, C., Bonfils, C., Gelmon, K., Siu, L. L., Tolcher, A., Carducci, M., Besterman, J. M., Reid, G. K. and Li, Z. (2005) Pharmacodynamic effect of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, on HDAC enzyme inhibition and histone acetylation induction in phase I clinical trials in patients (pts) with advanced solid tumors or non-Hodgkin's lymphoma (NHL). J. Clin. Oncol. 23, 9631
33. Gelmon, K., Tolcher, A., Carducci, M., Reid, G. K., Li, Z., Kalita, A., Callejas, V., Longstreth, J., Besterman, J. M. and Siu, L. L. (2005) Phase I trials of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3 x weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors, J. Clin. Oncol. 23, 3147
34. Gurvich, N., Berman, M. G., Wittner, B. S., Gentleman, R. C., Klein, P. S. and Green, J. B. (2005) Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo. FASEB J. 19, 1166-1168
35. Kramer, O. H., Zhu, P., Ostendorff, H. P., Golebiewski, M., Tiefenbach, J., Peters, M. A., Brill, B., Groner, B., Bach, I., Heinzel, T. and Gottlicher, M. (2003) The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 22, 3411-3420
36. Kaiser, M., Zavrski, I., Sterz, J., Jakob, C., Fleissner, C., Kloetzel, P. M., Sezer, O. and Heider, U. (2006) The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 91, 248-251
37. Kuendgen, A., Schmid, M., Schlenk, R., Knipp, S., Hildebrandt, B., Steidl, C., Germing, U., Haas, R., Dohner, H. and Gattermann, N. (2006) The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 106, 112-119
38. Morotti, A., Cilloni, D., Messa, F., Arruga, F., Defilippi, I., Carturan, S., Catalano, R., Rosso, V., Chiarenza, A., Pilatrino, C. et al. (2006) Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells. Cancer 106, 1188-1196
39. Gantt, S. L., Gattis, S. G. and Fierke, C. A. (2006) Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion. Biochemistry 45, 6170-6178
40. Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X. F. and Yao, T. P. (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417, 455-458
41. Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S. and Matthias, P. (2003) HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 22, 1168-1179
42. Kawaguchi, Y., Kovacs, J. J., McLaurin, A., Vance, J. M., Ito, A. and Yao, T. P. (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115, 727-738
43. Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P. et al. (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280, 26729-26734
44. Sharp, S. and Workman, P. (2006) Inhibitors of the HSP90 molecular chaperone: current status. Adv. Cancer Res. 95, 323-348
45. Steele, N., Vidal, L., Plumb, J., Attard, G., Rasmussen, A., Buhl-Jensen, P., Brown, R., Blagden, S., Evans, J. and de Bono, J. (2005) A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours. J. Clin. Oncol. (Meet. Abstr.) 23, 3035
46. Duvic, M. and Vu, J. (2007) Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin. Invest. Drugs 16, 1111-1120
47. Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M. and Duvic, M. (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25, 3109-3115
48. Rasheed, W. K., Johnstone, R. W. and Prince, R. M. (2007) Histone deacetylase inhibitors in cancer therapy. Expert Opin. Invest. Drugs 16, 659-678
49. Piekarz, R. L., Sacked, D. L. and Bates, S. E. (2007) Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J. 13, 30-39
50. Marchion, D. and Munster, P. (2007) Development of histone deacetylase inhibitors for cancer treatment. Expert Rev. Anticancer Ther. 74, 583-598